Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | XTX301 |
Synonyms | |
Therapy Description |
XTX301 comprises IL-12 linked to an IL12RB2-derived masking domain via a protease-sensitive linker that is cleaved by proteases in the tumor microenvironment, which activates IL-12 signaling and potentially inhibits tumor growth (PMID: 38030380). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
XTX301 | XTX 301|XTX-301 | XTX301 comprises IL-12 linked to an IL12RB2-derived masking domain via a protease-sensitive linker that is cleaved by proteases in the tumor microenvironment, which activates IL-12 signaling and potentially inhibits tumor growth (PMID: 38030380). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT05684965 | Phase I | XTX301 | XTX301 in Patients With Advanced Solid Tumors | Recruiting | USA | 0 |